Journal article

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34( ) Yields Are Less

David F Stroncek, Bronwen E Shaw, Brent R Logan, Deidre M Kiefer, Bipin N Savani, Paolo Anderlini, Christopher N Bredeson, Peiman Hematti, Siddhartha Ganguly, Miguel Angel Diaz, Hisham Abdel-Azim, Ibrahim Ahmed, Dipnarine Maharaj, Matthew Seftel, Amer Beitinjaneh, Sachiko Seo, Jean A Yared, Joerg Halter, Paul V O'Donnell, Gregory A Hale Show all

Biology of Blood and Marrow Transplantation | ELSEVIER SCIENCE INC | Published : 2018


Awarded by National Cancer Institute (NCI)

Awarded by NHLBI

Awarded by Health Resources and Services Administration

Awarded by Office of Naval Research

Funding Acknowledgements

This study was supported in part by research funding from the Clinical Center, National Institutes of Health, Bethesda, Maryland, USA (to D.F.S.). The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; a grant/cooperative agreement 4U10HL069294 from the NHLBI and NCI; 2 contracts HHSH250201200016C (MCW) and HHSH250201200024C (NMDP) with the Health Resources and Services Administration; 2 grants N00014-17-1-2388 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be The Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; Medlmmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd. - Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Asterisk indicates Corporate Members.